Earnings ·
Caribou reports Q3 net loss of $26.6M and announces restructuring to explore strategic alternatives
CRBUCaribou Biosciences, Inc.
Caribou Biosciences reported a third-quarter GAAP net loss of $26.6 million, or $0.25 per share, on November 5, 2026. The company disclosed that its board approved a restructuring plan to explore strategic alternatives, including potential mergers, acquisitions, or liquidation. This decision follows the planned discontinuation of clinical trials for vispa-cel and CB-011 due to financing challenges in the allogeneic CAR-T cell therapy market. The restructuring includes a substantial workforce reduction and other cost-cutting measures. As of September 30, 2026, Caribou held $94.8 million in cash, cash equivalents, and marketable securities. Caribou Biosciences operates as a clinical-stage CRISPR genome-editing biopharmaceutical company.